Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM4B | O94953 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28300532 | 0.78 | MAPK1 (0.50) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL2172238 | 0.77 | KDM4A (0.42) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL8671607 | 0.77 | KDM4A (0.42) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL12613954 | 0.77 | KDM4A (0.42) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL952863 | 0.77 | NOTUM (0.48) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL20394404 | 0.77 | ADORA2A (0.45) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL18209362 | 0.77 | ALDH1A1 (0.50) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL18414244 | 0.76 | ADORA2A (0.51) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL21407089 | 0.76 | ALDH1A1 (0.48) | ADORA2AADORA3ADORA2BADORA1KDM4A | |
| SCHEMBL21407080 | 0.76 | NOTUM (0.43) | ADORA2AADORA3ADORA2BADORA1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957214-A | Preparation method of chlorantraniliprole intermediate | 九江善水科技股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114957214-A | Preparation method of chlorantraniliprole intermediate | 九江善水科技股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-3377496-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1670801-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| US-5789584-A | Substituted-pyridinyl cephalosporin antibiotics active against methicillin resistant bacteria | MICROCIDE PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5756493-A | ACTIVE AGAINST METHICILLIN RESISTANT BACTERIA | MICROCIDE PHARMACEUTICALS, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5698547-A | 7-(ACYLAMINO)-3-(ARYLTHIO)-3-CEPHEM-4-CARBOXYLIC ACIDS WHICH EXHIBIT ANTIBACTERIAL ACTIVITY AGAINST ORGANISMS RESISTANT TO BETA-LACTAM ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-12-16 | — | — | US | disclosed |
| CN-1149874-A | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS INC (US) | 1997-05-14 | — | — | CN | disclosed |
| US-5607926-A | ACTIVE AGAINST METHICILLIN RESISTANT BACTERIA | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5604218-A | EXHIBITS ACTIVITY AGAINST METHICILLIN RESISTANT BACTERIA | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0754184-A1 | CEPHALOSPORIN ANTIBIOTICS | Microcide Pharmaceuticals, Inc. (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5593986-A | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996038450-A1 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1995026966-A1 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | ADORA2A 150/4885ADORA3 99/4885ADORA2B 41/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | ADORA2A 150/4885ADORA3 99/4885ADORA2B 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.